Include All CSL Sites

Locations - Our combined footprint

The combination of bioCSL with the influenza vaccine division of Novartis has created the second largest flu company in the world: Seqirus.

With extensive research and production expertise and manufacturing plants in the US, UK, Germany and Australia, Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally.


In Argentina the influenza vaccines business of Novartis will continue to be operated by Novartis under the Novartis brand until local regulatory approval is obtained.